Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gyrus Group PLC

Division of Olympus Corp.
www.gyrusmedical.com

Latest From Gyrus Group PLC

Olympus Dives Back Into M&A With Image Stream Medical Buy

When Olympus Corp. re-entered the M&A arena after five years of "back to the basics," it was via the purchase of a company that meets every parameter of its requirements. Nacho Abia says that OR integrator Image Stream Medical should also help the Japanese multinational stay on course to meet value-based – and ambitious mid-term sales – targets.

Deals M & A

Olympus Targets A Bigger Medical Future

A medical company that has some other businesses – that is the shorthand description that Olympus Corp. of the Americas president and CEO Nacho Abia ascribes to a group that has emerged from difficult times with a new strategy, new structure and new determination. Targeted deals and M&A remain as important as ever to the group as it embarks, somewhat reinvented, on a new five-year plan.

Growth Business Strategies

Buyer Appetite Might Appeal To GI Device Investors

A long-time darling of venture capital, the gastrointestinal sector has yet to meet expectation of VCs who wagered on technologies to treat gastroesophageal reflux disease, Barrett’s esophagus and even obesity. But some notable acquisitions, including Covidien’s purchase of privately held Barrx, may present a ray of hope for investors in GI companies.

Medical Device North America

Covidien Still Hungry For GI After Barrx Buy

Just as it did with VNUS, Covidien snapped up a smaller leader in a field where it had very little contact – esophageal cancer and its precursor Barrett’s esophagus – with the intent of building a larger presence. Covidien paid $325 million for Barrx Medical Inc., developer of a radiofrequency tool capable of eliminating Barrett’s, a condition in which damaged esophageal tissue presents an elevated risk of developing into esophageal cancer.

Medical Device North America
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register